Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Material

Supplemental Table 1. Numbers of participants according to changes in eGFR and UACR.

Supplemental Figure 1. Study design and identification of the study cohort.

Supplemental Figure 2. Diagram showing the grouping of participants according to a combination of change in albuminuria category and percent change in UACR.

Supplemental Figure 3. Diagram showing the grouping of participants according to baseline and change in A) eGFR and B) UACR to account for regression to the mean, using a 40% cut-off for the changes in eGFR and UACR.

Supplemental Figure 4. Diagram showing the grouping of participants according to baseline and change in A) eGFR and B) UACR to account for regression to the mean, using a 10% cut-off for the changes in eGFR and UACR.

Supplemental Figure 5. Sensitivity analysis; Adjusted associations of 2-year changes in eGFR or UACR with the risk of subsequent major clinical outcomes, after exclusion of randomized BP and glucose control treatments and change in systolic BP were excluded from covariates, or additional adjustment for change in HbA_{1c}.

Supplemental Figure 6. Sensitivity analysis; Adjusted associations of 2-year changes in UACR with the risk of subsequent major clinical outcomes, using different definitions.

Supplemental Figure 7. Sensitivity analysis; Adjusted associations of 2-year changes in eGFR or UACR with the risk of subsequent major clinical outcomes, using a 30% cut-off for the changes in eGFR and UACR.

Supplemental Figure 8. Sensitivity analysis; Adjusted associations of 2-year changes in eGFR or UACR with the risk of subsequent major clinical outcomes, after adjusting for regression to the mean, using a 40% cut-off for the changes in eGFR and UACR.

Supplemental Figure 9. Sensitivity analysis; Adjusted associations of 2-year changes in eGFR or UACR with the risk of subsequent major clinical outcomes, after adjusting for regression to the mean, using a 10% cut-off for the changes in eGFR and UACR.

Supplemental Figure 10. Sensitivity analysis; Adjusted associations of combination of 2-year changes in eGFR and UACR with the risk of subsequent major clinical outcomes, using a 30% cut-off for the changes in eGFR and UACR.

Supplemental Figure 11. Sensitivity analysis; Adjusted associations of combination of 2-year changes in eGFR and UACR with the risk of subsequent major clinical outcomes, after adjusting for regression to the mean, using a 40% cut-off for the changes in eGFR and UACR.

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Table 1. Numbers of participants according to changes in eGFR and UACR

A)

	Change in eGFR			
	Increased ≥40%	Minor change	Decreased ≥40%	Total
Change in UACR				
Decreased ≥40%	91 (1) [23 (1)]	2352 (27) [591 (27)]	72 (1) [23 (1)]	2515 (29) [637 (29)]
Minor change	101 (1) [26 (1)]	2805 (32) [634 (29)]	96 (1) [28 (1)]	3002 (34) [688 (31)]
Increased ≥40%	112 (1) [24 (1)]	3029 (35) [801 (37)]	108 (1) [41 (2)]	3249 (37) [866 (40)]
Total	304 (3) [73 (3)]	8186 (93) [2026 (92)]	276 (3) [92 (4)]	

Number in parentheses represents %.

Number in brackets represents number of events.

B)

	Change in eGFR			
	Increased ≥30%	Minor change	Decreased ≥30%	Total
Change in UACR				
Decreased ≥30%	198 (2) [43 (2)]	2539 (29) [614 (28)]	224 (3) [76 (3)]	2961 (34) [733 (33)]
Minor change	141 (2) [34 (2)]	1968 (22) [453 (21)]	188 (2) [50 (2)]	2297 (26) [537 (25)]
Increased ≥30%	238 (3) [55 (3)]	2982 (34) [765 (35)]	288 (3) [101 (5)]	3508 (40) [921 (42)]
Total	577 (8) [132 (6)]	7489 (85) [1832 (84)]	700 (7) [227 (10)]	

Number in parentheses represents %.

Number in brackets represents number of events.

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 1



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 2



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 3



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 4



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 5



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 6



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 7



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 8



Supplemental Figure 9



Supplemental Figure 10

Combined major macrovascular, kidney events, and all-cause mortality



	Change in eGFR		
	Increased ≥30%	Minor change	Decreased ≥30%
Change in UACR			
Decreased ≥30%	0.73 (0.53, 1.00)	0.94 (0.83, 1.06)	1.23 (0.96, 1.58)
Minor change	0.93 (0.65, 1.32)	1.00 (Reference)	1.31 (0.98, 1.76)
Increased ≥30%	0.92 (0.69, 1.23)	1.25 (1.11, 1.41)	1.93 (1.55, 2.41)

Major macrovascular events



	Change in eGFR		
	Increased ≥30%	Minor change	Decreased ≥30%
Change in UACR			
Decreased ≥30%	0.68 (0.45, 1.01)	0.91 (0.78, 1.07)	1.27 (0.93, 1.73)
Minor change	1.03 (0.68, 1.55)	1.00 (Reference)	0.99 (0.69, 1.48)
Increased ≥30%	0.70 (0.48, 1.04)	1.20 (1.03, 1.38)	1.72 (1.32, 2.26)

Major kidney events



	Change in eGFR		
	Increased ≥30%	Minor change	Decreased ≥30%
Change in UACR			
Decreased ≥30%	0.18 (0.02, 1.33)	0.76 (0.41, 1.39)	3.02 (1.29, 7.07)
Minor change	0.62 (0.14, 2.73)	1.00 (Reference)	5.32 (2.24, 12.67)
Increased ≥30%	Not calculated	1.46 (0.79, 2.69)	14.16 (7.07, 28.37)

All-cause mortality



	Change in eGFR		
	Increased ≥30%	Minor change	Decreased ≥30%
Change in UACR			
Decreased ≥30%	0.57 (0.36, 0.90)	0.99 (0.84, 1.15)	1.20 (0.88, 1.63)
Minor change	0.79 (0.49, 1.27)	1.00 (Reference)	1.60 (1.12, 2.27)
Increased ≥30%	1.07 (0.75, 1.51)	1.34 (1.15, 1.55)	2.76 (2.14, 3.56)

Supplemental Figure 11

Combined major macrovascular, kidney events, and all-cause mortality



	Change in eGFR		
	Residual increase	RtM	Residual decrease
Change in UACR			
Residual decrease	0.75 (0.61, 0.92)	0.78 (0.65, 0.94)	0.83 (0.67, 1.02)
RtM	0.90 (0.77, 1.05)	1.00 (Reference)	1.14 (0.99, 1.32)
Residual increase	1.14 (0.96, 1.36)	1.15 (0.98, 1.36)	1.47 (1.26, 1.71)

Major macrovascular events



	Change in eGFR		
	Residual increase	RtM	Residual decrease
Change in UACR			
Residual decrease	0.65 (0.50, 0.85)	0.81 (0.64, 1.02)	0.80 (0.62, 1.05)
RtM	0.96 (0.79, 1.15)	1.00 (Reference)	1.03 (0.85, 1.24)
Residual increase	1.11 (0.90, 1.37)	1.06 (0.87, 1.30)	1.36 (1.12, 1.65)

Major kidney events



	Change in eGFR		
	Residual increase	RtM	Residual decrease
Change in UACR			
Residual decrease	1.62. (0.43, 6.08)	Not calculated	3.16 (0.91, 11.0)
RtM	0.98 (0.28, 3.39)	1.00 (Reference)	7.82 (3.03, 20.2)
Residual increase	3.05 (1.01, 9.15)	3.71 (1.29, 10.72)	14.46 (5.64, 37.04)

All-cause mortality



	Change in eGFR		
	Residual increase	RtM	Residual decrease
Change in UACR			
Residual decrease	0.86 (0.66, 1.12)	0.78 (0.61, 1.00)	0.89 (0.69, 1.14)
RtM	0.88 (0.71, 1.09)	1.00 (Reference)	1.32 (1.10, 1.58)
Residual increase	1.23 (0.98, 1.55)	1.31 (1.07, 1.61)	1.72 (1.43, 2.07)